Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

HER3 inhibitors

Daiichi Sankyo logo

Daiichi Sankyo begins sharing clinical trial data online

Joins the likes of GSK, Lilly, UCB and Astellas in opening up its records

- PMLiVE

Tresiba safer than insulin glargine, says Novo Nordisk

Trial compares its basal insulin with Sanofi's Lantus

Roche Basel Switzerland

Roche shares slip as profits miss expectations

But shows solid sales growth thanks to its oncology portfolio

- PMLiVE

Alkermes depression drug misses targets in phase III

Irish firm suffers major research setback with ALKS 5461

EISAI

Eisai’s Lenvima gets FDA priority review for kidney cancer

The oncology treatment could now be approved in the US before the summer

- PMLiVE

French government begins investigation into fatal Biotrial study

First-in-man trial leaves one dead, five hospitalised

- PMLiVE

Merck & Co buys IOmet to boost immuno-oncology tech

Reports suggest it paid up to £280m for the Scottish biopharma company

- PMLiVE

AbbVie takes ‘one-size-fits-all’ HCV regimen into phase III

Comes shortly after Gilead wins priority FDA review for its 'pan-genotypic' treatment

- PMLiVE

ViiV and Janssen plan pivotal trials of monthly HIV treatment

Rilpivirine – cabotegravir combination could provide a monthly option

- PMLiVE

Up in smoke

The side-lining of efficacy in medical cannabis debates

- PMLiVE

Less is more: how risk-based monitoring is changing trials

A quality risk management approach is one of the biggest drivers for change in clinical research

Roche Basel Switzerland

Roche’s lung cancer drug Alecensa gets FDA OK

Wins accelerated US approval for non-small cell lung cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links